Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Thoracic Oncology - Volume 13, Issue 6, June 2018, Pages e89-e91

Roberta PhD, Paola MD, PhD, Silvia PhD, Anna Squadrilli, Alessandro MD, Lorena PhD, Cinzia PhD, Costanza Anna Maria Lagrasta, Letizia MD, Nicoletta Campanini, Pier Giorgio PhD, Roberta PhD, Marcello MD, PhD,